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Abstract
Background Gastrointestinal (GI) mucositis caused by che-
motherapy is associated with diarrhoea and intestinal barrier
disruption caused by apoptosis, immune dysfunction and
mic rob iome a l t e ra t ions . Se rum-der ived bov ine
immunoglobulin/protein isolate (SBI) has been shown to
manage HIV-associated enteropathy and irritable bowel syn-
drome with diarrhoea (IBS-D). We investigated in a rat model
whether SBI was effective in alleviating symptoms of
irinotecan-induced GI mucositis.
Methods Animals were gavaged with 250 or 500 mg/kg of
SBI twice daily for 4 days, before intraperitoneal administra-
tion of 200 mg/kg irinotecan. Twice daily gavaging of SBI
continued for 6 days post-irinotecan. Animals were monitored
for bodyweight changes and incidence of diarrhoea and clin-
ical symptoms of stress. Tissues and blood samples were col-
lected at necropsy 6 h, and 2, 4 and 6 days post-irinotecan.
H&E-stained colon and jejunum were analysed for histologi-
cal damage.
Results The overall incidence, severity and duration of diar-
rhoea, and clinical symptoms of mucositis were decreased in
irinotecan-treated animals that had received SBI. Animals re-
ceiving 500 mg/kg SBI also tended to lose less bodyweight
than animals treated only with irinotecan (P>0.10). SBI-
gavaged animals had less pronounced irinotecan-induced
changes in neutrophil (P=0.04959) and lymphocyte (P=
0.0035) levels, and lower tissue damage scores than those
receiving irinotecan alone (P<0.0001).
Conclusions Twice daily oral gavage of SBI was well-
tolerated and reduced the incidence, severity and duration of
irinotecan-induced mucositis. SBI was associated with less
pronounced changes in inflammatory cell levels and tissue
damage to colon and jejunum. Ongoing experiments aim to
investigate the mechanisms of SBI-associated gastrointestinal
protection.
Keywords Mucositis .Animalmodel .Serum-derivedbovine
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Introduction
Chemotherapy-induced gastrointestinal mucositis (CIGM)
can not only necessitate treatment delay or cessation but also,
more importantly, represent a significant burden to healthcare
costs and patient quality of life [1]. Symptoms include diar-
rhoea, abdominal pain and weight loss and are a direct result
of damage to the epithelial layer of the gut, which increases
permeability, induces inflammation and ulceration, and pre-
vents adequate nutrient uptake. Alterations to the gut
microbiome are also associated with mucositis, which can
further drive the inflammatory state [2, 3]. At present, treat-
ment for mucositis is supportive only; new interventions
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intended to prevent and/or reduce mucositis are being inves-
tigated and include growth factors, anti-inflammatories, nutri-
tional supplements and medicinal foods [4].
Oral administration of serum-derived immunoglobulin, de-
rived from human or animal serum or plasma, has been shown
to improve symptoms of disease states with an inflammatory
basis, such as viral gastroenteritis in children [5],
malnourishment in children [6], weaning in pigs [7], irritable
bowel syndrome with diarrhoea (IBS-D) [8, 9] and HIV-
induced enteropathy [10]. Serum-derived bovine
immunoglobulin/protein isolate (SBI) is obtained through
the spray-drying of bovine plasma and is available commer-
cially as EnteraGam™ (Entera Health Inc., Cary, NC, USA),
which is regulated by the FDA as a medical food in the man-
agement of IBS-D [8, 9] and HIV-associated enteropathy [10].
The aforementioned enteropathic conditions are associated
with abdominal pain, weight loss, malabsorption and diar-
rhoea, and as such have a similar symptom profile to CIGM.
With this in mind, the rationale for the current study was to
determine whether SBI had similar positive effects on
irinotecan-induced GI mucositis in a Dark Agouti rat model.
Methods and materials
Animals
Animal work complied with the National Health and Medical
Research Council (Australia) Code for the Care and Use of
Animals for Scientific Purposes (8th edition, 2013). Ethics
approval was obtained from both University of Adelaide and
SA Pathology. Animals were group-housed (four animals/
cage) in standard conditions of light and dark cycles and had
food and water available ad libitum.
Female Dark Agouti rats (n=192) of 150–180 g were ran-
domly assigned to treatment groups. Our models of
chemotherapy-induced mucositis focus on growing (non-
adult) animals, as younger animals are more responsive to
chemotherapy.
Serum-derived bovine immunoglobulin/protein isolate
SBI was provided by Entera Health Inc. as a >90 % (w/
w) protein powder, comprised of >50 % immunoglobulin
G (IgG), and a mixture of other serum proteins similar to
that found in milk and colostrum. Additional ingredients
are dextrose and trace amounts of sunflower lecithin. SBI
is free of milk products (lactose, casein, whey), gluten,
dye and soy, and is manufactured in accordance with
current Good Manufacturing Practice (cGMP) for medi-
cal foods [9]. Powdered SBI was mixed with water for
dosing as recommended in the prescribing information,
and the doses used in this study (250 and 500 mg/kg)
were based around the daily human equivalent dose (~5–
10 g/day [10, 8, 9]); average gavage volume was 1.5–
2 mL.
Experimental plan
On experimental day 4, animals were orally gavaged twice
daily (at 8 a.m. and 3 p.m.) with either 250 or 500 mg/kg of
SBI, or an equivalent volume of 0.09 % saline. This was
continued for 11 days. On day 0, 200 mg/kg of irinotecan
was administered intraperitoneally to appropriate groups, with
0.01 mg/kg of subcutaneous atropine to prevent a cholinergic
reaction.
Animals were monitored for 6 h following irinotecan ad-
ministration for clinical signs of stress; at this time point, eight
animals in each treatment group were killed. Approximately
4 mL of blood was collected for analysis. Animals were dis-
sected; intestinal tissue was removed and flushed with chilled
saline, and organs were removed, then all tissues were
weighed and fixed in formalin. Remaining animals continued
to receive twice daily oral gavage; on days 2, 4 and 6 post-
treatment, eight animals in each group were killed. Animals
were weighed and monitored for clinical symptoms of stress
and diarrhoea up to four times daily; these include
piloerection, stress marks (porphyrin discharge from
Harderian glands), changes in movement, temperament and
posture, reduction in temperature, weight loss, and reduced
food and water intake. These symptoms were scored as 0
(none), 1 (mild), 2 (moderate) or 3 (severe), and incidence
data were charted. Incidence of irinotecan-induced diarrhoea
was also charted for each animal, based on the following
established criteria [11]: 0 (none), 1 (mild; staining around
anus), 2 (moderate; staining around anus and top of hind legs)
and 3 (severe; staining over legs and abdomen, often with
continual oozing).
Histochemical, biochemical and morphometric
assessment
All experiments were performed in a blinded fashion. Blood
and serumwere sent to SA Pathology (FromeRoad, Adelaide)
for complete blood examination (CBE) and blood biochemis-
try tests (MBA-20). Formalin-fixed, paraffin-embedded jeju-
num and colon were cut into 4-μm sections and stained with
haematoxylin and eosin for damage scoring, or alcian
blue/periodic acid-Schiff mucin stain to assess changes in
goblet cells [12]. Immunohistochemistry to detect levels of
caspase-3 (apoptosis marker) and ki67 (proliferation marker)
[13] was also performed on 4-μm formalin-fixed, paraffin-
embedded sections. Microdissection to assess tissue mor-
phometry (villous area and crypt depth) was performed as
per established protocols [11, 14].
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Tissue damage scoring
Histopathological changes in H&E-stained colon and jejunum
were scored according to criteria described in Table 1. Scores
for each tissue section were tallied and represented as a per-
centage of the total score possible (20 for colon, 22 for
jejunum).
Statistical analyses
P values in the text represent two-way ANOVA with
Bonferroni post hoc testing, unless specified otherwise.
Results
Bodyweight
There was a clear separation in bodyweights 1 day post-
irinotecan administration, whereby animals receiving
irinotecan lost 5 % of bodyweight (approximately 10 g), re-
gardless of experimental group, compared to untreated ani-
mals (Fig. 1a, b). On day 2, this separation reached signifi-
cance (P<0.0001, Fig. 1a, b) and continued throughout the
study. While irinotecan-treated animals gavaged with
500 mg/kg SBI lost less weight than other groups, this failed
to reach significance (P=0.10; Fig. 1a, b).
Clinical signs of stress and diarrhoea
There were no clinical symptoms in the 4-day pre-treatment
period, so data are presented from day 0 onwards. Peak symp-
tom incidence and severity in treated controls were on day 3,
with 82 % of animals experiencing symptoms, 16 % of these
with severe symptoms (Fig. 2a). Administration of 250 mg/kg
SBI reduced the overall incidence and severity of symptoms
from days 1–5, with complete resolution of symptoms by day
5, 11 % less animals experiencing grade 3 symptoms overall
and 28 % less experiencing grade 2 symptoms (Fig. 2b). Ad-
ministration of 500 mg/kg SBI also reduced the overall inci-
dence and severity of symptoms from days 1 to 6, with 11 %
less animals experiencing grade 3 symptoms overall (Fig. 2c).
All rats receiving irinotecan developed diarrhoea, which
peaked on days 3 and 4; administration of SBI reduced the
overall incidence, severity and duration of irinotecan-induced
diarrhoea (Fig. 2d–f). Incidence of grade 2 diarrhoea was re-
duced in animals gavaged with 250 mg/kg SBI (Fig. 2e) com-
pared to treated controls (Fig. 2d) on day 0 (6 vs 9%), day 2 (4
vs 29 %), day 3 (18 vs 19 %) and day 4 (27 vs 44 %), and
incidence of grade 3 diarrhoea was reduced on day 3 (50 vs
62 %) and day 5 (14 vs 25 %). This reduction was even more
pronounced in animals gavaged with 500 mg/kg SBI, with all
diarrhoea symptoms resolving by day 5 (Fig. 2f), and a
reduction in grade 2 diarrhoea compared to treated controls
on day 0 (0 vs 9 %), day 2 (13 vs 29 %), day 4 (21 vs 44 %),
and a reduction of grade 3 diarrhoea on day 2 (0 vs 17 %), a
significant reduction on day 3 (log rank P value =0.0219, 31
vs 62%), and reductions on day 4 (29 vs 31%) and day 5 (0 vs
25 %).
Necropsy
Upon necropsy, animals treated with irinotecan (especially
treated controls compared to SBI-gavaged animals) had an
inflamed peritoneal cavity, particularly in the intestines and
mesentery. SBI-administered animals also had less pro-
nounced intestinal lymphatic nodules (Peyer’s patches) than
treated controls. While there were significant differences in
organ weights at necropsy in all irinotecan-treated animals
compared to untreated controls, post hoc analyses failed to
identify specific differences associated with SBI
administration.
CBE and MBA-20
There were no significant changes in all untreated, SBI-
gavaged groups compared to untreated controls; these groups
have therefore been omitted from graphs to enhance visual
clarity. Administration of SBI had no influence on any
MBA-20 parameters.
Six hours after irinotecan treatment, there was an increase
in the white cell count (WCC) in irinotecan-treated groups
(Fig. 3a) that was largely driven by an increase in neutrophil
numbers (Fig. 3b) and was less pronounced in groups given
SBI, although this failed to reach significance. On days 2 and
4 post-treatment, WCCs in irinotecan-treated groups were sig-
nificantly decreased compared to untreated controls
(P<0.0001), with SBI-gavaged groups showing a less pro-
nounced, non-significant decrease at these time points
(Fig. 3a). On day 6 post-treatment, however, WCCs in
250mg/kg SBI-gavaged animals remained significantly lower
than untreated and treated controls (P=0.0141 and P=0.0018,
respectively, Holm-Sidak t test), suggesting that WCCs in this
group had failed to reach normal levels by the end of the study.
Animals administered 500 mg/kg SBI also had lower WCC
than untreated controls at the end of the study; however, this
failed to reach significance (Fig. 3a).
At 6 h post-irinotecan treatment, there was a highly signif-
icant increase in neutrophils (as % of total WCC) in irinotecan
groups (Fig. 3b; P<0.0001); however, this increase was less
pronounced in groups administered SBI (non-significant;
Fig. 3b). A similar pattern was observed 2 days post-
irinotecan treatment. At 4 days post-treatment, all irinotecan-
treated animals showed a significant neutropenia when com-
pared to untreated controls (P<0.0001); however, post hoc
analyses failed to identify differences between SBI-gavaged
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animals and treated controls. After 6 days, neutrophil levels in
all irinotecan-treated groups had recovered almost to normal
levels; however, animals administered 500 mg/kg SBI were
significantly closer to normal levels (untreated controls) than
treated controls (Fig. 3b; P=0.04959, Holm Sidak t test).
Conversely, at 6 h and 2 days post-irinotecan treat-
ment, lymphocyte levels (as % of total WCC) were
significantly decreased in all irinotecan groups and sig-
nificantly increased on day 4 compared to untreated
controls (Fig. 3c; P<0.0001). These changes were less
marked in SBI-gavaged groups (non-significant). This
trend reached significance 6 days post-irinotecan treat-
ment in both SBI groups versus treated controls
(Fig. 3c; P=0.0469, P=0.0035, respectively, Holm
Sidak t test), where percentage of lymphocytes
approached normal levels (untreated controls). Similarly
to neutrophil levels, recovery of lymphocytes to normal
levels was more pronounced in animals administered
SBI compared to treated controls.
Histology and tissue damage scoring
There was a greater degree of irinotecan-induced damage
in the colon than the jejunum (Fig. 4a, f), regardless of
experimental group. In sections of jejunum from treated
controls, villous atrophy, blunting and fusion was marked
(Fig. 4b), and in colon and jejunum, cryptolysis was
widespread, with severe attenuation of lining enterocytes,
presence of apoptotic bodies in crypts, marked polymor-
phonuclear cell infiltrate within the lamina propria and
accumulation of mucous and cellular debris within an
enlarged lumen (Fig. 4b, d, g, i). Peyer’s patches within
the submucosa were often enlarged. Irinotecan-treated in-
testinal tissues also demonstrated an increased vascularity
Table 1 Tissue damage scoring
Jejunum Colon
Crypt ablation (CA) 1=markedly decreased length of crypts
2=complete ablation of crypts (ghost crypts)
1=markedly decreased length of crypts
2=complete ablation of crypts (ghost crypts)
Flattening of colonic folds (FC) N/A 1=moderate flattening of folds and loss of surface
area
2=marked flattening of folds (loss ofmore than half of
normal folded area)
Villous ablation/blunting (VA/B) 1=villi < two thirds of normal length
2=villi < one third of normal length
NA
Villous fusion (VF) 1=one or two fused villi throughout tissue
2=majority of villi fused throughout tissue
N/A
Mucosal ulcerations (MU) 1=small superficial ulcerations
2=individual ulcerations (in total) involving
approximately one third of intestinal circumference
3=large ulcerations involving more than half of the
intestinal circumference
1=small superficial ulcerations
2=individual ulcerations (in total) involving
approximately one third of intestinal circumference
3=large ulcerations involving more than half of the
intestinal circumference
Inflammation (I) (increase in gut-
associated lymphoid tissue, GALT)
1=widespread infiltrate of single WBCs
2=widespread infiltrate+patches of WBCs discrete
from ulcerations
1=widespread infiltrate of single WBCs
2=widespread infiltrate+patches of WBCs discrete
from ulcerations
Apoptosis (A) 1=widespread distribution of single apoptotic cells in
crypts
2=patches of crypt apoptosis in crypts
1=widespread distribution of single apoptotic cells in
crypts
2=patches of crypt apoptosis in crypts
Tissue disorganisation (TD) 1=disorientated crypts in some areas
2=disorientated crypts throughout tissue
1=disorientated crypts in some areas
2=disorientated crypts throughout tissue
Epithelial cell sloughing (ECS) 1=discreet areas of lining epithelium sloughed into
lumen
2=majority of lining epithelial layer gone
1=discreet areas of lining epithelium sloughed into
lumen
2=majority of lining epithelial layer gone
Lymphatic congestion (LC) 1=Dilated lymph vessels or cystic collections of
lymph
2=markedly dilated lymph vessels with large cystic
collections of lymph
1=Dilated lymph vessels or cystic collections of
lymph
2=markedly dilated lymph vessels with large cystic
collections of lymph
Blood vessel congestion (BVC) 1=few individual vessels full of RBCs in discreet
areas
2=approximately half of blood vessels are full of
RBCs throughout the entire tissue
3=majority of visible blood vessels completely full of
RBCs, vessels appear distended
1=few individual vessels full of RBCs in discreet
areas
2=approximately half of blood vessels are full of
RBCs throughout the entire tissue
3=majority of visible blood vessels completely full of
RBCs, vessels appear distended
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within the lamina propria (Fig. 4b) and dilated lacteals,
which were often congested with lymphatic fluid. Patho-
logical changes had for the most part resolved by day 6
post-treatment; however, in some tissues, villous fusion
and blunting, lymphatic dilation and inflammation were
still observed (Fig. 4d, i).
Irinotecan-treated tissues from groups administered SBI at
both 250 and 500 mg/kg displayed similar changes to those
seen above; however, there was a visible decrease in crypt
ablation (jejunum and colon; Fig. 4c, h) and villous ablation
(jejunum, Fig. 4c, e) compared to treated controls (Fig. 4b, g).
Overall, tissue architecture was preserved more noticeably in
tissues derived from SBI-gavaged animals compared to treat-
ed controls (Fig. 4c, e, h, j). Presence of apoptotic cells within
crypts at 6 h (Fig. 4c, h) and 2 days post-treatment was less
prominent in jejunum and colon tissue derived from SBI-
administered animals. Inflammatory cell infiltrate was also
less pronounced.
Histopathological changes were then quantitated using
the damage scoring system (Table 1). Untreated, SBI-
gavaged animals showed very low damage scores (0–1)
similar to untreated controls and so have been omitted
from graphs.
Administration of SBI resulted in significantly lower
damage scores at all time points in jejunum and colon
(Fig. 5; P<0.0001). This reduction in irinotecan-induced
damage reached significance in 250 mg/kg SBI-gavaged
animals compared to treated controls, at 6 h post-
treatment in jejunum (Fig. 5a; 35.8±1.81 vs 44.0±2.54)
and colon (Fig. 5b; 30.7±2.97 vs 43.6±2.83), 2 days
post-treatment in jejunum (Fig. 5a; 42.6±4.62 vs 57.6±
3.83) and colon (Fig. 5b; 25.6±1.75 vs 36.3±2.80) and
at 6 days post-treatment in jejunum (Fig. 5a; 9.99±3.64
vs 21.6±2.06) and colon (Fig. 5b; 13.6±2.61 vs 26.4±
2.37). Administration of 500 mg/kg SBI also significant-
ly reduced irinotecan-induced damage in the colon at 6 h
Fig. 1 a Bodyweight as
percentage change from baseline.
b Bodyweight in grams. Graphs
represent data±SEM. Data was
analysed via two-way ANOVA,
with the Bonferroni post hoc test
Fig. 2 Incidence of clinical signs of stress and diarrhoea. Graphs
represent incidence of daily scores for each group, expressed as a
percentage. Statistical significance for decreased grade 3 diarrhoea on
day 3 in animals treated with 500 mg/kg SBI and irinotecan vs
irinotecan controls (log rank P value=0.0219, 31 vs 62 %) is marked
with an asterisk
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post-treatment (Fig. 5b; 33.1 ±3.77 vs 43.6± 2.83;
P<0.0001), 2 days post-treatment (Fig. 5b; 22.9±3.06
vs 36.3±2.80), and 4 days post-treatment (Fig. 5b; 29.2
±2.39 vs 37.1±2.41) and 6 days post-treatment in the
jejunum (Fig. 5a; 13.6±2.83 vs 21.6±2.06) and colon
(Fig. 5b; 18.1±3.13 vs 26.4±2.37).
Alcian blue, periodic acid/Schiff staining of goblet cells
Increased numbers of cavitated goblet cells have been associ-
ated with chemotherapy-induced gut injury [15]; in this study,
however, there were no significant differences attributable to
SBI treatment.
Fig. 3 Total white cell count (WCC) and neutrophil and lymphocyte levels as a percentage of the total WCC. Graph represents data±SEM. Data was
analysed via two-way ANOVA, with the Bonferroni post hoc analysis
Fig. 4 H&E-stained 4-μm sections of jejunum and colon. Bars represent
100 μm; all sections, original magnification ×100. a Untreated colon. b
Irinotecan-treated colon 6 h post-treatment. Arrows show apoptosis (A),
mucus/epithelial cell sloughing (M/ECS), tissue disorganisation (TD) and
crypt ablation (CA). c SBI-treated, irinotecan-treated colon, 6 h post-
treatment. Note less TD, less CA, less A, than in b. d Irinotecan-treated
colon 6 days post-treatment. Arrows show polymorphonuclear cells
(PMNs) within the lamina propria. e SBI-treated, irinotecan-treated
colon, 6 days post-treatment. Note less PMN infiltrate than in d. f
Untreated jejunum. g Irinotecan-treated jejunum 6 h post-treatment.
Arrows show villous ablation/blunting/fusion (VA/B/F), PMNs, A, CA,
TD and blood vessel congestion (BVC). h SBI-treated, irinotecan-treated
jejunum, 6 h post-treatment. Note less TD, less VA/B/F, less A, less BVC
than in g. i Irinotecan-treated jejunum 6 days post-treatment. Arrows
show PMN infiltrate, villous fusion (VF) and lymphatic congestion
(LC). j SBI-treated, irinotecan-treated jejunum, 6 days post-treatment.
Note higher degree of tissue organisation, no LC or VF, and slightly less
PMN infiltrate in the lamina propria
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Morphometry
In the jejunum, villous area of all irinotecan-treated animals
was significantly increased on day 6 post-treatment compared
to untreated controls (P<0.0001; due to rebound hyperplasia);
however, SBI administration was not associated with any sig-
nificant differences between groups.
Immunohistochemistry to assess proliferation
and apoptosis
Levels of proliferating and apoptotic cells were consistent
with irinotecan treatment; however, analysis failed to high-
light differences between SBI-gavaged and saline-treated an-
imals in either the jejunum or colon.
Discussion
In the current study, twice daily administration of SBI was
well-tolerated and resulted in reduction in the incidence, se-
verity and duration of irinotecan-induced clinical signs of
stress and diarrhoea, as well as a significant reduction in his-
topathological damage in the intestines. There is evidence that
the basis for these observations is modulation of the inflam-
matory response associated with irinotecan-induced mucosi-
tis. The results herein are consistent with results observed in
similar animal intestinal studies, where SBI was utilized, and
also show similar symptom reduction as seen in patient studies
of enteropathies managed with SBI.
Since chemotherapy-induced GI mucositis (CIGM) has a
similar etiology and symptom profile to intestinal disorders
such as IBS-D and HIV-associated enteropathy, it is reason-
able to suggest that patients suffering fromCIGMwould show
similarly improved symptoms with SBI. The animal model
used in this study has been well established and has many
similarities to the patient setting; thus, we postulated that ad-
ministration of SBI would manage CIGM.
In a pilot study of 66 patients by Wilson et al. [8], daily
administration of 10 g of SBI over a period of 6 weeks signif-
icantly reduced the severity and frequency of symptoms of
IBS-D, such as abdominal pain, stool frequency, loose stools,
bloating, flatulence and urgency, compared to placebo (soy
protein isolate). Similarly, in a study of eight patients with
HIV-associated enteropathy by Asmuth [10], twice daily ad-
ministration of 2.5 g SBI for 8 weeks resulted in reduced
bowel movements and improved stool consistency in all pa-
tients. In the current study, irinotecan-treated rats gavaged
with human equivalent doses of SBI also showed a significant
reduction in the incidence, severity and duration of mucositis-
associated symptoms, such as diarrhoea.
Since the animals in this model were administered SBI
4 days prior to irinotecan treatment, it would be interesting
to see whether a longer period of pre-treatment SBI adminis-
tration would further improve diarrhoea and clinical symp-
toms of stress. Such preparatory dosingwould also be possible
in patients with CIGM (if SBI was given before irinotecan
administration); however, since patients with other enteropa-
thies present with these conditions before SBI administration
would be possible, benefits of preparatory dosing in these
conditions will remain unknown. A future animal study to
determine whether dosing with SBI at the onset of mucositis
symptoms (without preparatory dosing) is able to achieve the
same results as the current study would provide useful infor-
mation on the value of pre-treatment and determine whether
protective effects of SBI are transient or cumulative.
The lack of changes in bodyweights, organ weights, intes-
tinal goblet cells, morphometry, apoptosis and proliferation
suggest that SBI-associated attenuation of the clinical symp-
toms of mucositis is not dependent upon increased cell prolif-
eration and tissue growth as is observed after treatment with
growth factors designed to alleviate mucositis [16, 17]. Simi-
lar findings were made in rotavirus-infected pigs [18], where
SBI administration did not significantly increase weight gain
or alter tissue morphometry, and in weaning piglets, where
SBI administration showed few changes to intestinal mor-
phometry, and in fact resulted in lower small intestinal weight
over the treatment period [19].
SBI is high in glutamic acid, which is converted to gluta-
mine. Studies have shown that free glutamine is an essential
amino acid required during times of catabolic stress, such as
injury or disease, and is a preferential energy source not only
Fig. 5 Tissue damage scores.
Graph represents data±SEM.
Data was analysed via two-way
ANOVA, with the Bonferroni
post hoc analysis. Asterisks
represent significance when
compared to treated controls
(P<0.0001)
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for enterocytes but also for rapidly proliferating immune cells
[20, 21]. It is thus linked to the maintenance of intestinal
barrier function and cell differentiation and may contribute
to the positive effects of SBI as observed in this study, where
histopathological analyses showed that tissues from animals
administered SBI were more likely to retain proper architec-
ture and an intact epithelial layer.
One hypothesis for the positive effects of SBI in
enteropathic conditions is the modulation of intestinal im-
mune function in gut-associated lymphoid tissue (GALT)
and reduced levels of pro-inflammatory cytokines [7, 22,
23]. Oral administration of spray-dried plasma proteins was
associated with a decreased level of inflammatory cytokines in
organised (Peyer’s patches) and diffuse (lymphocytes in lam-
ina propria) GALT of the ileum and colon in weaning piglets,
which show similar symptoms to patients suffering from GI
mucositis, including malabsorption, diarrhoea and weight loss
associated with increased gut permeability [7]. Results obtain-
ed in the current study reflect these findings, as levels of cir-
culating and mucosal neutrophils and lymphocytes (diffuse
GALT) in irinotecan-treated animals receiving SBI were low-
er than those in treated controls. Anecdotal evidence of less
pronounced intestinal lymphatic nodules (organised GALT)
and less inflamed peritoneal cavities during necropsy also
supports this. Further studies to assess tissue levels of pro-
inflammatory cytokines are currently underway.
Analysis of histopathological damage showed significantly
lower damage scores in both colon and jejunum of irinotecan-
treated animals that had received both 250 and 500 mg/kg
SBI, compared to those that had not. The density of lymphoid
cells present in the lamina propria was decreased in gut tissues
from animals gavaged with SBI, which was reflected in com-
paratively lower total white cell counts and percentages of
neutrophils and lymphocytes in circulating blood. Reduced
damage scores were most pronounced 2 and 4 days post-
treatment in tissues from animals receiving SBI compared to
treated controls. This also supports the potential anti-
inflammatory role of SBI, suggesting that preparatory dosing
prior to irinotecan treatment is not enough to stop the initial
damage but helps to attenuate the induced inflammatory state
which further drives the damage.
Low-grade inflammation, either idiopathic or injury-in-
duced, is associated with increased epithelial permeability in
the gut due to degradation of occludin within tight junctions
[24]. Transepithelial bacterial translocation is then more likely
to occur, thus increasing lipopolysaccharide exposure to the
GALT, which then further drives the process through the re-
lease of pro-inflammatory cytokines, giving rise to clinical
symptoms such as diarrhoea, malabsorption and subsequent
weight loss. The process is thought to underpin chronic dis-
eases such as IBS-D [8] and HIV-associated enteropathy [10],
and physiologically stressful conditions such as malnutrition
[6] and weaning [25], and is often accompanied by changes to
the microbiota, which may further compound the inflamma-
tory process. Gastrointestinal mucositis initiated by cancer
therapy (chemotherapy, radiotherapy and targeted therapy)
occurs through direct damage to gut epithelium and creation
of reactive oxygen species; however, the subsequent mecha-
nisms of inflammation, increased gut permeability and clinical
symptoms are similar to the abovementioned conditions. It has
been shown that IgG in SBI binds lipopolysaccharide from
bacterial cell walls, thus protecting mucosal surfaces from
bacterial antigenic exposure [26, 27]. Similar binding effects
have also been demonstrated for endotoxins [22, 28, 23] and
rotavirus [18], further underpinning the importance of SBI in
management of enteropathies [29, 30]. Additional studies to
explore the role of SBI in attenuating the intestinal inflamma-
tory response and possible maintenance of the healthy micro-
biota in this animal model are currently underway.
The results from this study demonstrate that SBI shows
significant promise in the management of chemotherapy-
induced GI mucositis in an animal model. Positive effects of
SBI in the management other enteropathies with similar symp-
tom profiles in patients have also been demonstrated, perhaps
paving the way for similar use of SBI in the supportive care of
treatment-inducedmucositis. Further studies to underpin exact
mechanisms of action and effects on solid tumours are re-
quired, however, as well as comprehensive analyses of pro-
inflammatory cytokines within gut tissue and microbiome
alterations.
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